TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04977167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG146
Description: HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG146
Description: HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG146
Description: HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG146
Description: HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-(L)1 antibody
Description: PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-(L)1 antibody
Description: PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-(L)1 antibody
Description: PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
Study: NCT06463015

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guided posterior tibial nerve pulsed radiofrequency
Description: The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
Study: NCT06372093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Picterus Jaundice Pro is a smartphone based screening tool for neonatal jaundice that takes images of the skin of the newborn chest where the Picterus Calibration Card is placed.
Study: NCT04907240

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
Study: NCT05359042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Patient Reported Outcomes platform
Description: The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Related Quality of Life Surveys
Description: Surveys will be administered to participants
Study: NCT06159439

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound scan
Description: Contrast enhanced ultrasound using Sonovue microbubble contrast
Study: NCT05649657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyclic aerobic and resistance training
Description: Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25\~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2\~3 sessions per week and about 70 sessions in total.
Study: NCT06425120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuesaitong Soft Capsule
Description: Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant in the placebo group will take matching placebo.
Study: NCT05789927

Intervention type: PROCEDURE
Intervention: Assessment of the microbial exposome
Description: The assessment of the microbial exposome will be carried out by the deployment of 4 dust collectors (1 per season) at the patient's home. The evaluation of the endogenous myco-microbiome will be carried out by analyzing patient sputum obtained during follow-up visits or during routine care in the event of an exacerbation.
Study: NCT06108752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercises
Description: The scapular stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic extension exercises
Description: Thoracic extension exercises will be comprised of three exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
Study: NCT06159439

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Arterial-spin labelling magnetic resonance imaging
Study: NCT05959447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant + Gemfibrozil
Description: Camlipixant will be administered alone as well as in co-administration with gemfibrozil
Study: NCT05056350

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: back to work coaching
Description: Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
Study: NCT05959447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate + camlipixant
Description: Dabigatran etexilate will be administered alone as well as in co-administration with camlipixant
Study: NCT05388903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2325a
Description: Subcutaneous injection (starting dose 30 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2325a
Description: Intravenous infusion (starting dose 100 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT05464992

Intervention type: OTHER
Group type: OTHER
Intervention: Additional CEST sequences during PET/MRI exam
Description: CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
Study: NCT03435939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 50 mg/day for 7 days followed by 100 mg/day for 12 weeks
Study: NCT06146686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fanta AF blue rotary files 20 taper 4
Description: single rotary file Fanta AF blue rotary files 20 taper 4

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fanta AF baby rotary files 20 , 25 , 30 taper 4
Description: multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
Study: NCT04288115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
Study: NCT05512910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
Study: NCT05718882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product Plus VIC1911
Description: Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN.
Study: NCT05882968

Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests
Description: using GFR test according to kdigo guide lines
Study: NCT05884138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and nutritional support
Description: resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
Study: NCT06375031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; HR011408 injection Placebo
Description: Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; HR011408 injection Placebo
Description: Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; HR011408 injection Placebo
Description: Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid®; HR011408 injection Placebo
Description: Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid®; HR011408 injection Placebo
Description: Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid®; HR011408 injection Placebo
Description: Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection Placebo; HR011408 injection
Description: Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection Placebo; HR011408 injection
Description: Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection Placebo; HR011408 injection
Description: Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum
Study: NCT04593680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
Description: The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
Description: The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
Study: NCT05762120

Intervention type: OTHER
Group type: OTHER
Intervention: Weight Management Programme
Description: Weight Management Programme which consists of 4 phases:~1. Very low calorie diet~2. Low calorie diet~3. Maintenance phase~4. Continuance phase
Study: NCT05680168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal electromagnetic stimulation
Description: Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal electromagnetic stimulation
Description: Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises
Description: Pelvic floor muscle training in serial training sessions with our therapist
Study: NCT06540573

Intervention type: DIAGNOSTIC_TEST
Intervention: Physician global assessment (PhGA)
Description: Physician global assessment (PhGA)of disease activity will be reported by the physician.The Physician Global Assessment (PhGA) of treatment response measures the overall response to treatment as assessed by the physician. The PhGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. PhGA is a simple instrument and the result is easily understood. However, assigning a score for PhGA requires a very detailed evaluation. To perform this assessment a physician/health care provider would use extensive data from every aspect of ICF.

Intervention type: DIAGNOSTIC_TEST
Intervention: Physician global assessment (PhGA)
Description: Physician global assessment (PhGA)of disease activity will be reported by the physician.The Physician Global Assessment (PhGA) of treatment response measures the overall response to treatment as assessed by the physician. The PhGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. PhGA is a simple instrument and the result is easily understood. However, assigning a score for PhGA requires a very detailed evaluation. To perform this assessment a physician/health care provider would use extensive data from every aspect of ICF.
Study: NCT05680168

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises
Description: Pelvic floor muscle training in serial training sessions with our therapist
Study: NCT06540573

Intervention type: DIAGNOSTIC_TEST
Intervention: Health Assessment Questionnaire (HAQ)
Description: Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Health Assessment Questionnaire (HAQ)
Description: Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Health Assessment Questionnaire (HAQ)
Description: Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.
Study: NCT05054023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soulagel®
Description: topic gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arthrosyl®
Description: topic gel
Study: NCT06540573

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical disease activity index (CDAI)
Description: Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. CDAI is based on the simple summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76

Intervention type: DIAGNOSTIC_TEST
Intervention: The Simplified Disease Activity Index (SDAI)
Description: The Simplified Disease Activity Index for Rheumatoid Arthritis (SDAI) is a scoring system that has been validated in both research and clinical settings. It has been shown to have the highest sensitivity and specificity for predicting a physicians' decisions to change DMARD therapy when compared to other scores.Remission is defined as an SDAI of \<3.3, low disease activity as ≤11, moderate disease activity as ≤26 and high disease activity as \>26. Response to therapy is considered moderate if SDAI decreases by ≥7 and major if decreases by ≥17

Intervention type: DIAGNOSTIC_TEST
Intervention: Knee Radiography
Description: Knee osteoarthritis (gonarthrosis) will be evaluated using Kellgren-Lawrence (KL) staging on direct radiographs (anteroposterior and lateral views).Numerous variations of the Kellgren and Lawrence classification system have been used in research. Grade 0 (none): definite absence of x-ray changes of osteoarthritis. Grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping.Grade 2 (minimal): definite osteophytes and possible joint space narrowing. Grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone ends Grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends. Osteoarthritis is deemed present at grade 2 although of minimal severity